Last updated: 29 July 2020 at 9:20pm EST

Bio Ventures 2014, L.P.Evni... Net Worth




The estimated Net Worth of Bio Ventures 2014, L.P.Evni... is at least $415 Thousand dollars as of 28 July 2020. Bio Evni owns over 160,000 units of iTeos Therapeutics stock worth over $415,324 and over the last 4 years Bio sold ITOS stock worth over $0.

Bio Evni ITOS stock SEC Form 4 insiders trading

Bio has made over 1 trades of the iTeos Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Bio bought 160,000 units of ITOS stock worth $3,040,000 on 28 July 2020.

The largest trade Bio's ever made was buying 160,000 units of iTeos Therapeutics stock on 28 July 2020 worth over $3,040,000. On average, Bio trades about 160,000 units every 0 days since 2020. As of 28 July 2020 Bio still owns at least 25,974 units of iTeos Therapeutics stock.

You can see the complete history of Bio Evni stock trades at the bottom of the page.



Insiders trading at iTeos Therapeutics

Over the last 4 years, insiders at iTeos Therapeutics have traded over $196,492,023 worth of iTeos Therapeutics stock and bought 4,975,000 units worth $95,182,800 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Kol..., and Aaron I. Davis. On average, iTeos Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $1,817,279. The most recent stock trade was executed by Matthew Gall on 12 October 2023, trading 5,000 units of ITOS stock currently worth $41,850.



What does iTeos Therapeutics do?

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.



What does iTeos Therapeutics's logo look like?

iTeos Therapeutics, Inc. logo

Complete history of Bio Evni stock trades at iTeos Therapeutics

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
28 Jul 2020 Bio Ventures 2014, L.P.Evni...
Buy 160,000 $19.00 $3,040,000
28 Jul 2020
25,974


iTeos Therapeutics executives and stock owners

iTeos Therapeutics executives and other stock owners filed with the SEC include: